On December 20, 2024, the Food and Drug Administration conferred accelerated approval for encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in conjunction with cetuximab and mF...
June 2024: The Food and Drug Administration has given accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) in combination with cetuximab for adults who have KRAS G12C-mutat...
The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic colorectal cancer (mCRC) who have undergone sp...
March 2023: In 2020, nearly 2 million cases of colorectal cancer will be diagnosed globally, making it the third most prevalent cancer type. It is the second leading cause of cancer-related deaths, a...
In February 2023, the Food and Drug Administration (FDA) sped up the approval of tucatinib (Tukysa, Seagen Inc.) and trastuzumab for the treatment of RAS wild-type HER2-positive colorectal cancer tha...
July 6th 2021 : Colorectal cancer is the among most prevalent cause of cancer death in the the world. Regular screening, on the other hand, can detect colorectal cancer while it is tiny, hasn't sprea...
Gastrointestinal stromal tumor targeting drug Avapritinib (Avapriny, Ayvakit, BLU-285) is approved by USFDA on 9th January, 2020. The drug covers two indications: for the treatment of adult patients ...
Colon cancer immunotherapy, rectal cancer immunotherapy, colorectal cancer immunotherapy, and colorectal cancer PD-1 / PD-L1 treatment. Seventeen years ago, the number of drugs available for advanced...
Targeted treatment of colorectal cancer, BRAF V600E gene mutation targeted therapy of colorectal cancer Braftovi + Erbitux finally achieved positive resultsColorectal cancer treatment statusColorect...
How to prevent relapse of colorectal cancer, how to treat relapse of colorectal cancer after surgery?Colorectal cancer is a common malignant tumor, including colon cancer and rectal cancer. The inci...